Speaker illustration

Professor Alexander E Berezin

Paracelsus Private Medical University, Salzburg (Austria)

Member of:

European Society of Cardiology
Heart Failure Association

Dr. Alexander E. Berezin has received PhD in 1994 in the State Medical University of Zaporozhye (Ukraine). He is currently working as Senior Consultant, Lecturer and Professor of Medicine in the State Medical University of Zaporozhye (Ukraine). His research goals are fundamental study of biological markers, the development of cardiovascular prevention and rehabilitation. Based on this research and training in heart failure he has received several awards and honors. He has a regional and national profile. He has published 1050 papers and more in reputed journals, 57 books/chapters and has been serving as an editorial board member of repute.

The effect of sglt-2 inhibitor dapagliflozin on adropin serum levels in patients with chronic heart failure and concomitant type 2 diabetes mellitus

Event: ESC Congress 2023

Topic: Pharmacotherapy

Session: More insights into SGLT2i in heart failure

Thumbnail

Altered myokine profile and glycemic control in type 2 diabetes mellitus patients with heart failure

Event: Heart Failure 2023

Topic: Biomarkers

Session: Chronic heart Failure - biomarkers 2

Thumbnail

Altered myokine profile associated with glycemic control in type 2 diabetes mellitus patients with heart failure

Event: ESC Preventive Cardiology 2023

Topic: Biomarkers

Session: Moderated ePoster 23

Thumbnail

Impact of dapagliflosin on apelin serum levels in type 2 diabetes mellitus patients depending on occurrence of heart failure with preserved ejection fraction

Event: Heart Failure 2022

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Heart Failure ePosters - focus on Chronic Heart Failure 4

Thumbnail

Circulating levels of irisin and apelin predict heart failure with preserved ejection fraction in type 2 diabetes mellitus patients

Event: Frontiers in CardioVascular Biomedicine 2022

Topic: Heart Failure

Session: Poster Session 1

Thumbnail

Elevated levels of apelin predict favorable clinical course of heart failure in type 2 diabetes mellitus patients

Event: ESC Preventive Cardiology 2022

Topic: Biomarkers

Session: ePosters

Thumbnail

Predictive value of both irisin and apelin for heart failure with preserved ejection fraction in type 2 diabetes mellitus patients

Event: ESC Preventive Cardiology 2022

Topic: Biomarkers

Session: ePosters

Thumbnail

Predictive utility of apelin to nt-pro-brain natriuretic peptide ratio for heart failure with preserved ejection fraction among type 2 diabetes mellitus patients

Event: Heart Failure 2021

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: ePoster session

Thumbnail

Altered number of apoptotic-modified endothelial cells originated micro vesicles predict phenotypes of heart failure

Event: Heart Failure 2019

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: Chronic Heart Failure – Pathophysiology and Mechanisms

Thumbnail

Predictive value of growth differentiation factor-15 levels in chronic heart failure with reduced and mid-range ejection fraction with known diabetes mellitus

Event: Heart Failure 2019

Topic: Biomarkers

Session: Chronic Heart Failure – Diagnostic Methods

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb